1. Home
  2. Clinical Topics
  3. FDA targets companies selling unapproved products for treating opioid addiction
Clinical TopicsDrugs and DevicesWeb Exclusives
fda unapproved treatment opioid addiction

FDA targets companies selling unapproved products for treating opioid addiction

Share

On Jan. 24, the U.S. Food and Drug Administration (FDA) announced that along with the Federal Trade Commission it posted joint warning letters to the marketers and distributors of 12 opioid cessation products, for illegally marketing unapproved products with claims about their ability to help in the treatment of opioid addiction and withdrawal.

Read more via Fda.gov.

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts